$46.92▲ 0.18 (0.39%)
Real-time prices · US MarketsHigh-quality business with 60% return on equity and 35% profit margins.
earnings contracting 21% year-over-year.
Quality
10
Health
5.9
Growth
3.8
Valuation
6.5
Sentiment
4
Analyst Target
$47.40
▲ +1.0% from current
Price Chart
Latest News
- Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars
- Is the Weight-Loss Drug Market Really a Winner-Take-All Fight Between Novo Nordisk (NVO) and Eli Lilly (LLY)?
- LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
Fundamentals
Trailing P/E
11.4×
price-to-earnings
Forward P/E
13.6×
next 12 months est.
Market Cap
$207.5B
market capitalization
Div Yield
3.83%
dividend yield
Profit Margin
35.3%
net profit margin
Gross Margin
82.0%
revenue minus COGS
ROE
59.8%
return on equity
Beta
0.35
vs S&P 500
52-Week Range
$35 — $64
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Novo Nordisk A/S right now?
Novo Nordisk A/S's Q·Score is 6.3/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 60% return on equity and 35% profit margins. Key area to monitor: earnings contracting 21% year-over-year. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for NVO?
The consensus price target for NVO is $47.40, based on ratings from 12 Wall Street analysts. This is 1.0% above the current price of $46.92. Price targets are forward-looking estimates and not guarantees of future performance.
Is NVO overvalued or undervalued?
Novo Nordisk A/S (NVO) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 13.6×.
When does Novo Nordisk A/S report its next earnings?
Novo Nordisk A/S's next earnings report is expected on approximately November 4, 2026.
What is Novo Nordisk A/S's profit margin?
Novo Nordisk A/S has a net profit margin of 35.3%, which is considered high and reflects strong pricing power. Its gross margin stands at 82.0%, indicating a high-margin business model.
What is NVO's dividend yield?
Novo Nordisk A/S currently offers a dividend yield of 3.83%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.
Is Novo Nordisk A/S's revenue growing?
Novo Nordisk A/S is reporting modest revenue growth of 2.1%. However, earnings declined 20.6%, which warrants monitoring.
How much debt does Novo Nordisk A/S have?
Novo Nordisk A/S has a debt-to-equity ratio of 0.63×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 0.87×, suggesting it should be monitored for near-term liquidity.
Compare NVO with any stock